Physician profile
Jason Charles Hadley
NPI 1619148129
$293,883.23
in general payments reported to CMS, 2019-2025
34 companies · $139K in 2025
The $139K reported for 2025 was more than what 98% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $7,576 · 2020: $6,672 · 2021: $759 · 2022: $37K · 2023: $11K · 2024: $91K · 2025: $139K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $210K · Travel and Lodging: $22K · Food and Beverage: $8,190 · Consulting Fee: $1,440 · Honoraria: $252.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $209,850.00 |
| Travel and Lodging | $21,672.42 |
| Food and Beverage | $8,189.86 |
| Consulting Fee | $1,440.00 |
| Honoraria | $251.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Galderma Laboratories, L.P. | $153,188.44 | 2019-2025 | Nemluvio, Dysport, Aklief |
| Abbvie INC. | $134,464.31 | 2019-2025 | |
| Genentech USA, INC. | $1,611.85 | 2019-2025 | Xolair |
| Novartis Pharmaceuticals Corporation | $827.38 | 2020-2025 | |
| Dermavant Sciences, INC. | $578.42 | 2023-2024 | Vtama |
| Ucb, INC. | $560.44 | 2020-2025 | Bimzelx |
| Allergan, INC. | $363.64 | 2020-2022 | |
| Pfizer INC. | $292.81 | 2019-2025 | |
| Sun Pharmaceutical Industries INC. | $249.52 | 2019-2025 | Winlevi, Absorica Ld, Ilumya |
| Amgen INC. | $187.98 | 2019-2025 | Otezla, Otezla |
| Biofrontera INC. | $164.72 | 2021-2024 | Xepi, Bf-Rhodoled, Ameluz |
| Dermira, INC. | $160.52 | 2019-2021 | |
| Leo Pharma INC. | $159.45 | 2021-2025 | Adbry, Anzupgo |
| Lilly USA, LLC | $128.17 | 2019-2025 | Ebglyss, Taltz |
| Genzyme Corporation | $124.32 | 2019-2024 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vyne Pharmaceuticals INC. | $121.32 | 2020-2021 | |
| Janssen Biotech, INC. | $106.70 | 2023-2025 | Tremfya |
| Arcutis Biotherapeutics, INC. | $103.49 | 2023-2025 | Zoryve |
| Regeneron Healthcare Solutions, INC. | $84.69 | 2019-2025 | Libtayo |
| Organon LLC | $74.95 | 2024-2025 | Vtama |
| E.R. Squibb & Sons, L.L.C. | $73.81 | 2023-2025 | Sotyktu |
| Incyte Corporation | $55.51 | 2022-2025 | Opzelura |
| Mimedx Group, INC. | $43.09 | 2024-2025 | |
| Mylan Pharmaceuticals INC. | $25.97 | 2019 | |
| Strata Skin Sciences, INC. | $23.32 | 2025 | Xtrac |
| Krystal Biotech INC | $21.31 | 2024 | Vyjuvek |
| Boehringer Ingelheim Pharmaceuticals, INC. | $18.56 | 2022 | |
| Qiagen, LLC | $18.09 | 2020 | |
| Helsinn Therapeutics (U.S.), INC. | $15.99 | 2019 | |
| Merck Sharp & Dohme LLC | $14.90 | 2019 | |
| Botanix Sb INC | $13.54 | 2025 | Sofdra |
| Sensus Healthcare, INC. | $6.02 | 2020 |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jason Hadley listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.